Sydney M Crago

Health Canada approves Aflivu, a biosimilar for retinal diseases, enhancing treatment options and affordability for Canadian patients.

Phil Lai, MD, chief medical officer of Perfuse Therapeutics, said the company's goal is to pioneer disease-modifying treatment that targets an underlying pathology of ischemia

At the Retina World Congress, we spoke with Siegfried Priglinger, MD, about ensuring the best outcomes for preschool-aged patients

Williams joins Topcon Healthcare from Heidelberg Engineering, where she held multiple senior leadership roles.

Members of the Ophthalmology Times Europe, Ophthalmology Times and Modern Retina editorial advisory boards are present and presenting at the 2025 ARVO meeting

LuxIA is designed to screen adult diabetic patients for more-than-mild diabetic retinopathy.

Therapies for retinal vascular disease, dry eye disease, inflammation following glaucoma filtration surgery and more

In an established animal model of age-related macular degeneration, Eleva’s recombinant human CPV-104 improved two hallmarks of the disease

Regulatory agencies issued approvals for new treatments and expanded uses of existing therapies in the retina space

The initiative marks the second annual ROP Awareness week, running from 24 February to 2 March, 2025

Sara M. Thomasy, DVM, PhD, DACVO, discusses the importance of examining how glaucoma affects companion animals like dogs, cats and horses

The interventional glaucoma mindset can maximise quality of life, but requires clinicians to act fast

Hot topics around the globe, from clinical trials to the solar eclipse

Espansione Group's Light Modulation Low-level Light Therapy (LLLT) is used in ophthalmology and dermatology

The annual meeting held in Chicago, Illinois, featured new data and best practices for patient-centred care

OCU410ST is indicated for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa and cone-rod dystrophy 3 (CORD3)

ARVN001 is indicated for the treatment of uveitic macular oedema and certain other ophthalmic indications

OPUVIZ, previously known as the biosimilar candidate SB15, has been approved for the treatment of nAMD, DME and other retinal diseases

The positive opinion marks a key regulatory step towards the approval of FYB203, which will go by the trade names AHZANTIVE and Baiama in the European Union

The biosimilar to reference aflibercept (Eylea, Bayer AG) is indicated to treat retinal diseases including neovascular age-related macular degeneration

HG202, by HuidaGene Therapeutics, is formulated for clinical use in treating neovascular age-related macular degeneration

Research indicates suppressive valacyclovir could help patients avoid keratitis and iritis flare-ups

Victoria L. Tseng, MD, PhD, discusses SLT, microshunts and what glaucoma specialists can learn from large data sets

Michael Singer, MD, shared insights from on his experience using a preservative-free, chloroprocaine ophthalmic gel as anesthesia for intravitreal injections and the results of research on the effectiveness of gel versus traditional drops.

Brent Kramer, MD, presents on an alternative to IV sedation for cataract surgeries and complex cases

Nathan Radcliffe, MD, shared insights from his presentation at the annual meeting of the American Academy of Ophthalmology entitled, "Early cataract extraction for angle closure glaucoma."

George O. Waring, IV, MD provides insights from an on-demand poster as part of the annual American Academy of Ophthalmology taking place in Chicago, Illinois. This poster shared data on the the 9-month FDA data of the recently approved excimer laser, the TENEO laser, by Bausch + Lomb.

Dr. Arepalli discussed a course focused on ocular conditions related to pregnancy and postpartum care, presented at the American Academy of Ophthalmology (AAO) meeting.

At this year's American Academy of Ophthalmology (AAO) meeting, Jonathan Brugger, MD, spoke about the changing approach to epimacular membranes and the use of brilliant blue in the procedure.